Armistice Capital LLC Lowers Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Armistice Capital LLC reduced its holdings in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 7.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,506,000 shares of the company’s stock after selling 210,000 shares during the period. Armistice Capital LLC owned about 7.02% of Checkpoint Therapeutics worth $5,388,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Choreo LLC increased its position in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after acquiring an additional 7,080 shares during the period. XTX Topco Ltd acquired a new stake in Checkpoint Therapeutics in the 2nd quarter valued at about $34,000. Lindbrook Capital LLC purchased a new position in shares of Checkpoint Therapeutics in the 1st quarter valued at about $62,000. 180 Wealth Advisors LLC acquired a new position in shares of Checkpoint Therapeutics during the second quarter worth about $96,000. Finally, B. Riley Wealth Advisors Inc. increased its stake in shares of Checkpoint Therapeutics by 232.3% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock worth $374,000 after buying an additional 114,200 shares during the period. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT opened at $2.24 on Thursday. The firm has a market capitalization of $100.84 million, a PE ratio of -0.81 and a beta of 1.29. The business’s fifty day moving average price is $2.32 and its 200 day moving average price is $2.03. Checkpoint Therapeutics, Inc. has a 12 month low of $1.30 and a 12 month high of $3.62.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.11. The business had revenue of $0.04 million during the quarter. As a group, equities analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, September 16th.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.